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Abstract
Background: The prevalence, incidence and persistence of human papillomavirus (HPV) types in sub-Saharan
Africa are not well established. The objectives of the current study are to describe (predictors of) the epidemiology
of HPV among high-risk women in Kigali, Rwanda.
Methods: HIV-negative, high-risk women were seen quarterly for one year, and once in Year 2. HIV serostatus,
clinical, and behavioral information were assessed at each visit, HPV types at Month 6 and Year 2, and other
sexually transmitted infections (STI) at selected visits. HPV prevalence was also assessed in HIV-positive, high-risk
women.
Results: Prevalence of any HPV was 47.0% in HIV-negative women (median age 25 years) compared to 72.2% in
HIV-positive women (median age 27 years; OR 2.9, 95% CI 1.9-4.6). Among HIV-negative women, cumulative
incidence of high-risk (HR)-HPV was 28.0% and persistence 32.0% after a mean period of 16.6 and 16.9 months,
respectively. Prior Chlamydia trachomatis and Neisseria gonorrhoeae infection, concurrent low-risk (LR)-HPV infection
and incident HSV-2 were associated with HR-HPV prevalence among HIV-negative women; prior C. trachomatis
infection and co-infection with LR-HPV and HPV16-related HPV types with HR-HPV acquisition. HPV16-related types
were the most prevalent and persistent.
Conclusions: High HPV prevalence, incidence and persistence were found among high-risk women in Kigali.
HPV52 had the highest incidence; and, together with HPV33 and HPV58, were strongly associated with acquisition
of other HR-HPV types in HIV-negative women.
Background
Human papillomavirus (HPV) is the most common
sexually transmitted infection (STIs) worldwide [1]. Pre-
valence is highest among sexually active women below
25-35 years, usually declining thereafter [2,3]. World-
wide age-adjusted HPV prevalence in women with nor-
mal cytology is estimated at 12%, ranging from 5% in
Northern America to 34% in East Africa% [3]. Age and
high-risk sexual behavior (such as high life-time number
of sex partners and recent acquisition of a new sex
partner) are well-recognized risk factors for acquiring
HPV. Moreover, higher HPV prevalence rates have been
documented among women at high risk for other STIs
and among HIV-positive women [4,5]. Most infections
are cleared within two years but a minority of infections
becomes persistent [6]. Persistent infection with high-
risk (HR), oncogenic HPV genotypes is causally asso-
ciated with the development of cervical cancer, the most
common malignancy among women in Sub-Saharan
Africa [7].
An increasing number of articles report on the type-
specific HPV prevalence among women in Sub-Saharan
Africa, but incidence and persistence data remain scarce.
HPV dynamics, and predictors of incidence and
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data. This information will aid in the design of primary
or secondary prevention programs.
As part of secondary data-analysis of an HIV inci-
dence study, we evaluated HPV prevalence, incidence,
persistence, and their predictors, among HIV-negative
high-risk women in Kigali, Rwanda. In addition, HPV
prevalence was assessed among HIV-positive high-risk
women cross-sectionally.
Methods
Study population
A cross-sectional HIV prevalence survey was conducted
a m o n gh i g h - r i s kw o m e ni nK i g a l i ,R w a n d a .S u b s e -
quently, women testing HIV-negative during the survey,
and who were 18 years or older, at high risk for HIV
(defined as having exchanged sex for money at least
once in the last month and/or currently having sex with
multiple partners plus having sex at least twice per
w e e k )a n dw e r en o tp r e g n a n ta te n r o l m e n to rp l a n n i n g
a pregnancy within the next year were invited to partici-
pate in a prospective cohort study to assess HIV inci-
dence (2006-2009) [8].
T h et a r g e ts a m p l es i z ef o rt h eH I V - n e g a t i v ec o h o r t
was 400 and this was based on the primary HIV inci-
dence objective. HPV prevalence, incidence and persis-
tence were among secondary objectives of the study.
Enrolled women were followed quarterly for one year,
and were invited for one additional visit during year 2
("Year 2 visit”).
Women testing HIV-positive during the survey were
excluded from cohort participation, but were invited for
one additional study visit during year 2 ("Year 2 visit”)
during which HPV prevalence was assessed.
Women were recruited via community meetings in
three districts in Kigali. Written informed consent was
obtained, including parental or guardian consent for
women who were 18-20 years old. The study was con-
ducted at Projet Ubuzima, an international non-govern-
mental organization that operates a research clinic and
laboratory, in Kigali, Rwanda.
Study procedures for HIV-negative participants
HIV-negative participants were tested for HIV at every
study visit, for Neisseria gonorrhoeae, C. trachomatis, Tre-
ponema pallidum (syphilis), Trichomonas vaginalis,a n d
bacterial vaginosis (BV) at enrolment, Month 6, and
Month 12, and for BV also in Year 2. HPV typing and cer-
vical cytology were done at Month 6 and Year 2. HSV-2
serology testing was performed at enrolment, at Month 12
for women testing negative at enrolment, and in Year 2
for women testing negative at Month 12. Standardized
questionnaires were administered at each study visit.
Study procedures for HIV-positive participants
HIV-positive women participating in the Year 2 visit fol-
lowed the same study procedures as described for the
Year 2 visit of the HIV-negative cohort participants.
Women with abnormal cytology results were referred
for visual inspection with acetic acid (VIA) and colpo-
scopy by a gynecologist, and were offered appropriate
treatment. Women with curable STIs received treatment
and were offered partner notification and treatment.
HIV-positive women were referred to HIV care. As part
of the study procedures women received HIV preven-
tion, safer sex and family planning counseling at each
visit.
Human papillomavirus typing
HPV genotyping was performed at the Institute of Tro-
pical Medicine (ITM, Antwerp, Belgium) using the Lin-
ear Array HPV Genotyping Test (LA) (Roche Molecular
Systems, USA) according to manufacturer’s instructions.
In brief, cervical cells collected in Liquid Based Cytology
media PreservCyt were stored at -80°C until testing. An
aliquot of 250 μl was used for DNA extraction by
AmpliLute Liquid Media Extraction Kit (Roche Molecu-
lar Systems, USA). HPV genotype targets were amplified
using standard polymerase chain reaction (PCR). LA
applies PGMY09/11 L1 as consensus primer system and
co-amplifies human b-globulin as a cellular, extraction
and inhibition control. Reverse line blot hybridization
and detection identifies 37 high- and low-risk HPV
types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 53,
54, 55, 56, 58, 59, 61, 62, 64, 66 to 73, 81, 82 subtype
IS39, 82, 83, 84, CP108 and a mixed probe for types 33/
35/52/58). An in-house Real-Time PCR (RT-PCR) was
established at the ITM to identify DNA of HPV geno-
type 52 in the mixed probe positive samples. Briefly,
DNA was prepared using the NucliSens miniMAG (Bio-
Mιrieux, Boxtel, the Netherlands). DNA templates were
amplified in a qualitative RT-PCR assay. HPV52-F/R
and hydrolysis probe HPV52 labeled at the 5’ with FAM
and at the 3’ with BHQ-1 (Eurogentec, Belgium) were
used for amplification and detection [9]. Amplification
was performed using the Absolute Blue QPCR mix kit
(Thermo Scientific, UK), 500 nm of each primer and
probe, and 10 μL of DNA template, in a final reaction
volume of 30 μL. The RT-PCR was performed on the
Rotor-Gene™ 6000 platform (Corbett Life Science,
USA) using the following thermal cycling conditions:
initial enzyme activation at 95°C for 15 min; followed by
60 cycles of 95°C for 15 sec, 58°C for 45 sec, and 65°C
for 45 sec. Detection of the fluorescence signal was
recorded using the setting for hydrolysis probes (470
nm, 510 nm) following the extension phase cycle by
cycle.
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HIV testing was done at Projet Ubuzima according to
the national testing guidelines, with two positive rapid
tests indicating an HIV diagnosis (First Response, Pre-
mier Medical Corporation, Daman, India; and Uni-Gold
HIV, Trinity Biotech Plc, Ireland), and a third rapid test
(Capillus, Trinidity Biotech Plc, Ireland) as tiebreaker.
Positive results were confirmed with Murex HIV Ag/Ab
Combination ELISA (Abbott Laboratories, Germany).
CD4 cytometry was performed at the National Reference
Laboratory in Kigali.
InPouch culture (Biomed Diagnostics, USA) was used
for T. vaginalis diagnosis. Syphilis was diagnosed using
RPR (Spinreact, Spain) and TPHA (Spinreact, Spain).
HerpeSelect-2 ELISA (Focus Technologies, USA) was
used for HSV-2 antibody testing. Optical density ≥ 3.5
were considered positive for HSV-2, and OD ≤ 1.1 nega-
tive. All tests were performed at Projet Ubuzima. Dry
swabs (BD Culturette™ EZ Collection), stored at -80°C
were used for Amplicor NG/CT PCR (Roche Molecular
Systems, USA) for N. gonorrhoeae and C. trachomatis
testing at ITM. Positive results were confirmed with a
strand displacement amplification assay (Probetec, Bec-
ton Dickinson, USA). External quality control for STI
testing at Projet Ubuzima was coordinated by ITM. BV
was diagnosed by Gram stain Nugent score. Nugent
scoring was performed at Projet Ubuzima; at the Aca-
demic Medical Center of the University of Amsterdam,
Department of Medical Microbiology; and at the
Amsterdam Municipal Health Service, Public Health
Laboratory. Conventional cytology was performed at
Ghent University Hospital, Belgium, using the Bethesda
system for classification [10].
Statistical analysis
Data were double-entered, and analyzed using STATA
9.2 (StatCorp, TX, USA). Baseline characteristics were
estimated as percentages with 95% confidence intervals
(CI) for binary and categorical variables; median and
interquartile range (IQR) for non-normally distributed
continuous variables or mean and standard deviations
for normally distributed continuous variables.
HPV classification
In these analyses, HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73, 82 and IS39 were considered HR-
HPV types [11-13]. All other types were considered LR-
HPV. HPV16-related types included HPV16, 31, 33, 35,
52, and 58. ‘Any HPV’ included HR and/or LR-HPV.
HPV prevalence
HR-HPV prevalence was estimated from the first HPV
results in both HIV-negative (Month 6) and HIV-posi-
tive women (Year 2). Multivariable logistic regression
models for predictors of HR or LR-HPV detection in
HIV-positive and HIV-negative women were fitted using
manual backward modeling. Variables associated with
the outcome with a P-value < 0.10 in univariable models
were included in the initial multivariable logistic regres-
sion model. Variables were retained in the model based
upon Wald statistics (P < 0.05) and/or likelihood ratio
tests for the overall fit of the model (P <0 . 1 ) .A g ew a s
included as a covariate in all models. Pair-wise correla-
tions between the variables in the final models were
investigated, and correlated variables were assessed for
interaction. The comparison group for HR-HPV analysis
included women without HR-HPV, irrespective of LR-
HPV detection. Concurrent LR-HPV was included as a
covariate. Similarly, the comparison group in LR-HPV
analysis included women without LR-HPV, irrespective
of HR-HPV, but concurrent HR-HPV was included as a
covariate. Age-adjusted odds ratios and 95% confidence
intervals (C.I.) were calculated comparing HPV preva-
lence among HIV-positive (n = 349) and HIV-negative
women (n = 126). Women with abnormal cytology
results (HIV-negative women n = 16; HIV positive
women n = 14) were excluded.
HPV incidence (HIV-negative women)
Type-specific HR-HPV incidence was defined as newly
detected type-specific HR-HPV at the second HPV mea-
surement (Year 2) among women free of the type of
interest at the first HPV measurement (Month 6). The
(cumulative) incidence was calculated over the mean
interval between Month 6 and Year 2 visit. All incident
type-specific HR-HPV cases were grouped together into
one binary incident HR-HPV outcome variable, with
women without incident HR-HPV as the referent group
(regardless of presence of other prevalent HR-HPV
types or prevalent or incident LR-HPV). The association
between prevalent HR-HPV types and incidence of
other HR-HPV types was assessed. First, univariable
associations between each type-specific HR-HPV at
Month 6 and subsequent acquisition of other HR-HPV
types were evaluated. To increase statistical power, types
were then grouped according to their phylogenetic
group and within group according to strength of the
association (0.1 >P < 0.1). These groups were included
in the final incidence model. Sensitivity analyses were
performed excluding women with any prevalent HR-
HPV and/or LR-HPV at Month 6 from the reference
group. These results are not shown because they were
similar to those of the incidence model as described
above. Of the 349 HIV-negative women with normal
cytology results and HPV results at Month 6, 296
women also had HPV results at Year 2 visit and contrib-
uted to the incidence analyses. Methods for multivari-
able logistic regression modeling were identical to those
for HPV prevalence.
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HR-HPV persistence was defined as women who tested
positive for the same HR-HPV type at both visits during
which HPV typing was performed (Month 6 and Year
2). Persistence was calculated over the mean interval
between these two visits. All persistent type-specific HR-
HPV cases were grouped into one binary persistent HR-
HPV outcome variable, irrespective of LR-HPV. The
reference group included women who cleared all HR-
HPV infections at the second visit that were present at
the first visit, but who may however tested positive for
new HPV types at the second HPV measurement. Of
the 111 HR-HPV positive women with normal cytology
at Month 6, 90 women also had HPV results at Year 2
visit and contributed to the persistence analyses. Multi-
variable logistic regression modeling was conducted as
described for HPV prevalence above.
Ethical approvals were obtained from the National
Ethics Committee and the National AIDS Control Com-
mission (CNLS) in Rwanda; the Institutional Review
Board of Columbia University Medical Center, New
York, USA; and the Medical Ethics Committee of the
University of Antwerp, Belgium.
Results
Study population characteristics
Eight hundred women participated in the HIV preva-
lence survey between October 2006 and August 2007
and 192 women tested HIV-positive. Four hundred
three (403) HIV-negative, non-pregnant women were
enrolled in the cohort. The flow-diagram of the study is
given in Figure 1. All women, except one, self-identified
as female sex worker (FSW). Median age at survey was
25 (IQR 22-28) for HIV-negative women and 27 (IQR
23-32) for HIV-positive women. Among HIV-negative
cohort participants, prevalence of N. gonorrhoeae was
10% (CI 7.3-13.6), C. trachomatis 5% (CI 2.7-7.2), T.
vaginalis 17% (CI 13.4-21.2), syphilis 7% (CI 4.7-10.1),
and BV 45% (CI 39.4-49.9).
Type-specific HPV prevalence in HIV-negative and HIV-
positive women
Among 349 HIV-negative women with no cervical
abnormalities, the HPV prevalence at the first HPV
measurement visit (Month 6) was 47.0% for any HPV,
31.8% for HR-HPV and 32.4% for LR-HPV. The five
most prevalent HR-HPV types among HIV-negative
women were HPV16 (5.4%), HPV45 (4.9%), and HPV52
(4.3%) HPV58 (4.0%) and HPV68 (3.7%) (Figure 2).
Infection with multiple HR-HPV types was present in
11.7% of HR-HPV positive/HIV-negative women.
A total of 126 HIV-positive women were tested for
HPV at the Year 2 visit, had valid HPV results, and did
not have cervical abnormalities. HPV prevalence among
these women was 72.2% for any HPV, 50.8% for HR-
HPV and 54.8% for LR-HPV. HIV-positive compared to
HIV-negative women were 2.9 times (CI 1.9-4.6) more
likely to have any HPV detected; 2.2 times (CI 1.5-3.4)
HR-HPV and 2.5 times (CI 1.7-3.9) LR-HPV. The five
most prevalent HR-HPV types among HIV-positive
women were HPV52 (13.9%), HPV58 (11.1%), HPV51
(11.1%), HPV16, HPV 45 and HPV35 (each 7.9%). Mul-
tiple HR-HPV types were detected in 29.4% of HR-HPV
positive/HIV-positive women.
Correlates of prevalent high- and low-risk HPV in HIV-
negative women
In univariable analysis, the odds of prevalent HR-HPV at
Month 6 were significantly lower among older, higher
educated, widowed/divorced, and multiparous (≥ 3 preg-
n a n c i e s )w o m e n( T a b l e1 ) .T h eo d d sw e r es i g n i f i c a n t l y
higher among women with N. gonorrhoeae or C. tracho-
matis infection at baseline or among women with con-
current BV or LR-HPV infection. Women experiencing
incident HSV-2 infection at Month 6 and women using
hormonal contraceptices for longer than 6 months were
also more likely to have HR-HPV detected at Month 6
(P < 0.05). Sexual behavior indicators (number of clients,
number of vaginal sex acts, condom use, age at sexual
debut, years as FSW) were not associated with HR-HPV
prevalence among this highly sexually active population.
In multivariable analysis, being single, having N. gonor-
rhoeae or C. trachomatis infection at baseline, concur-
rent LR-HPV infection, and incident HSV-2 infection
remained independent predictors of HR-HPV prevalence
among HIV-negative women (Table 1).
In univariable analysis, LR-HPV was negatively asso-
ciated with older age (P < 0.05) (data not shown). Hor-
monal contraceptive use for longer than 6 months and
co-infection with HR-HPV were positively associated
with LR-HPV (P <0 . 0 5 ) .A g e ,a n dc o n c u r r e n tH R - H P V
remained independently associated with LR-HPV in
multivariable analysis, and there was a trend in that
direction for hormonal contraceptive use for longer than
6 months (P = 0.059; data not shown).
Correlates of prevalent high- and low-risk HPV in HIV-
positive women
Among the 126 HIV-positive women with no cervical
abnormalities who attended the Year 2 visit and had
HPV results, prevalent HR-HPV was associated with
concurrent LR-HPV infection in uni- and multivariable
models (Table 1) There was some evidence of an
increased risk of HR-HPV detection among women
never/inconsistently using condoms, although this did
not reach statistical significance in multivariable model.
Other exposure indicators, CD4 count, use of combi-
nation antiretroviral therapy (cART), and the interaction
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survey (N=800)
HIV positive 
(n=192)
Eligible but 
cohort target 
met (n=122)
HIV-negative 
women enrolled 
(n=397)
M6 participants: 
n=349
M12 participants: 
n=343
Year 2 participants: 
n=296
HIV negative 
but otherwise 
ineligible 
(n=83)
8 LFU; 1 skipped visit; 
1 death; 9 HIV 
seroconversion; 
13 missing HPV 
results
4 HIV 
seroconversion; 
2 LFU 
5 HIV seroconversion*; 
39 LFU; 3 missing 
HPV results
Year 2 participants:
126 HIV positive
51 LFU; 
2 missing HPV 
results
14 abnormal 
cytology at Year 2
16 abnormal 
cytology results at 
Month 6
Figure 1 Flow diagram - HPV analysis data set (cytologically normal women). Footnote: Abbreviations: HIV = human immunodeficiency
virus; HPV = human papillomavirus; LFU = lost to follow-up *in total there were 6 HIV seroconversion between M12 and Year 2, but one
participant was already dropped from HPV data analysis set because of abnormal cytology results at M6. HPV genotyping and cervical cytology
was performed among HIV-negative women at Month 6 and Year 2 and among HIV-positive women at Year 2 only. Women with abnormal
cytology results are excluded from the HPV analysis dataset.
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HR-HPV detection.
HR-HPV incidence among HIV-negative women
Of the 296 women who contributed to the HPV inci-
dence analyses, incident HR-HPV types were detected in
28.0% (95% CI 23.0-33.1) after a mean interval of 16.6
months (SD 1.8). The mean duration between the two
HPV measurements was not significantly associated
with acquisition of type-specific HR-HPV (data not
shown). Among HR-HPV positive women at Month 6,
34.4% acquired a new HR-HPV type by Year 2, com-
pared to 24.8% among women who were HR-HPV nega-
tive at Month 6 (P = 0.087). Cumulative HR-HPV
incidence was 39.2% among LR-HPV positive women at
Month 6 compared to 22.1% among LR-HPV negative
women (P = 0.002).
HPV52 incidence was highest among the HIV-negative
high-risk women (Table 2). Women above the age of 30
were less likely to acquire HR-HPV types (Table 3). LR-
HPV and HR-HPV types 33 and/or 52 and/or 58 at
Month 6,C. trachomatis infection at Month 12, the pre-
ceding visit to the second HPV measurement, and con-
current LR-HPV were associated with increased risk of
HR-HPV acquisition. Furthermore, women who worked
continuously throughout follow-up as a FSW were at
increased risk for HR-HPV acquisition. Infection with
HPV16-related HPV types 33, 52 and 58 at Month 6, C.
trachomatis infection at Month 12, concurrent LR-HPV
and self-reported sex work remained independent pre-
dictors of HR-HPV incidence in multivariable analysis.
HR-HPV persistence
Ninety HIV-negative women without cervical abnormal-
ities contributed to the HR-HPV persistence analysis. Of
them, 32.0% had persistent HR-HPV at Year 2 after a
mean interval of 16.9 months (SD 1.7). Mean duration
between the two HPV measurements was not associated
with clearance or persistence. Persistence was most
common for HPV31 and 68 (data not shown). In uni-
variable analyses, only BV at Month 12 was associated
with a decreased likelihood of persistent HR-HPV infec-
tion (Table 3).
Discussion
We found high prevalence rates of HR-HPV (50.8% and
31.8%) and LR-HPV (54.8% and 32.4%) in HIV-positive
and HIV-negative high-risk Rwandan women, respec-
t i v e l y .T h i si sc o n s i d e r a b l yh i g h e rt h a nt h ep r e v a l e n c e
rates that we found in women from the general popula-
tion in Kigali, Rwanda (HR-HPV 19.9%; LR-HPV 20.5%;
unpublished data Veldhuijzen et al [14]). Our results are
in line with results from another study among HIV-
positive women in Kigali that reported a HR-HPV
Figure 2 Distribution of high-risk HPV types in HIV-negative (n = 349) and HIV-positive (n = 126) high-risk women with normal
cytology.
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Page 6 of 14Table 1 Correlates of HR-HPV in HIV-negative and HIV-positive high-risk women with normal cytology, Kigali, Rwanda
HIV negative women
1 HIV positive women
2
HR HPV positive Unadjusted OR (95% CI) Adjusted OR (95% CI) HR HPV positive Unadjusted OR
(95% CI)
Adjusted OR (95% CI)
n/N N = 349 N = 318 n/N N = 126 N = 126
Demographical characteristics at baseline
Age
< 30 yrs 99/281 1 1 42/75 1 1
≥ 30 yrs 12/68 0.39 (0.20-0.78) 0.62 (0.29-1.33) 22/51 0.60 (0.29-1.23) 0.71 (0.34-1.50)
Marital status
3 4
Never married 98/264 1 1 44/82 1
Widowed/Divorced 13/80 0.33 (0.17-0.63) 0.42 (0.20-0.85) 20/44 0.72 (0.34-1.51)
Education level
No formal schooling 29/72 1 12/30 1
Primary school (partial/completed) 76/246 0.66 (0.38-1.14) 46/81 1.97 (0.83-4.69)
Secondary school (partial/completed) 6/31 0.36 (0.13-1.00) 6/15 1.00 (0.28-3.59)
Sexual and reproductive characteristics at baseline
Age at sexual debut
< 15 yrs 18/43 1 9/16 1
15-19 yrs 79/249 0.65 (0.33-1.26) 49/92 0.89 (0.30-2.60)
≥ 20 yrs 13/53 0.45 (0.19-1.10) 6/18 0.39 (0.09-1.66)
Parity
< 3 pregnancies 80/224 1 40/70 1
≥ 3 pregnancies 31/125 0.59 (0.36-0.97) 24/55 0.58 (0.28-1.20)
Genital infections at baseline
Neisseria gonorrhoeae by PCR
negative 90/314 1 1 not done
Positive 21/35 3.73 (1.79-7.79) 3.19 (1.38-7.38) not done
Chlamydia trachomatis by PCR
negative 100/332 1 1 not done
Positive 11/17 4.25 (.51-12.0) 4.38 (1.30-14.77) not done
Trichomonas vaginalis by InPouch culture
negative 92/289 1 not done
Positive 19/60 0.99 (0.55-1.81) not done
HSV-2 serology
4
negative 40/142 1 7/12 1
Positive 59/181 1.23 (0.76-2.00) 53/108 0.69 (0.20-2.32)
Positive syphilis serology
5
negative 98/322 1 not done
Positive 12/26 1.96 (0.87-4.41) not done
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4Table 1 Correlates of HR-HPV in HIV-negative and HIV-positive high-risk women with normal cytology, Kigali, Rwanda (Continued)
BV by Nugent score
Normal (score 0-3) 39/140 1 not done
Intermediate flora (score 4-6) 10/48 0.68 (0.31-1.50) not done
BV (score 7-10) 54/146 1.52 (0.92-2.51) not done
Current sexual and reproductive characteristics
No of clients in the past week
0 1/15 0.14 (0.02-1.16) 18/44 1
1-4 35/103 1 29/54 1.68 (0.74-3.79)
5-9 33/107 0.70 (0.36-1.37) 7/14 1.44 (0.43-4.90)
≥ 10 41/121 1.13 (0.64-2.00) 10/14 3.61 (0.92-14.14)
No of vaginal sex acts in past month
0 6/8 7.96 (1.49-42.55) 6/20 1
1-24 49/179 1 47/83 3.05 (1.03-8.97)
≥ 25 56/161 1.41 (0.89-2.25) 11/23 2.14 (0.59-7.81)
Condom use during vaginal sex in the past month
Always 44/153 1 18/40 1
Never/sometimes 61/186 1.22 (0.76-1.93) 40/66 1.88 (0.84-4.22)
No sex 6/8 7.43 (1.38-40.0) 6/20 0.52 (0.16-1.68)
Hormonal contraceptive use
6
No or < 6 months 80/283 1 NA
> 6 months 29/63 2.16 (1.23-3.81) NA
Current genital co-infections
Neisseria gonorrhoeae by PCR
negative 97/315 1 not done
Positive 11/25 1.77 (0.77-4.04) not done
Chlamydia trachomatis by PCR
negative 105/327 1 not done
Positive 6/17 1.15 (0.41-3.21) not done
Trichomonas vaginalis by InPouch culture
negative 91/292 1 not done
Positive 19/54 1.20 (0.65-2.11) not done
HSV-2 serology
7
negative 36/139 1 5/9 1
Positive 70/197 1.58 (0.97-2.55) 59/117 0.81 (0.21-3.20)
HSV-2 serology
4
Negative (Enr-M6) 33/132 1 1 NA
Positive at enrollment 59/181 1.45 (0.88-2.40) 1.78 (1.01-3.12) NA
Incident at M6 7/10 7.00 (1.62-30.21) 6.69 (1.41-31.38) NA
Positive syphilis serology
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4Table 1 Correlates of HR-HPV in HIV-negative and HIV-positive high-risk women with normal cytology, Kigali, Rwanda (Continued)
negative 100/321 1 not done
Positive 9/24 1.33 (0.56-3.14) not done
Concurrent LR HPV infection
negative 51/236 1 1 22/57 1 1
Positive 60/113 4.11 (2.47-6.83) 3.77 (02.17-6.54) 42/69 2.48 (1.18-5.19) 2.31 (1.11-4-81)
BV by Nugent score
Normal (score 0-3) 57/149 1 16/35
Intermediate flora (score 4-6) 17/51 1.51 (0.76-3.03) 7/18
BV (score 7-10) 50/126 1.99 (1.18-3.36) 39/68
Current (Year 2) HIV-related indicators
CD4 count (copies/mL)- use of cART
> 350 - no cART NA 33/60 1
> 350 - cART NA 13/34 0.51 (0.21-1.21)
≤ 350 - no cART NA 7/15 0.72 (0.23-2.25)
≤ 350 - cART NA 10/15 1.64 (0.49-5.44)
1 HR-HPV in HIV-negative women at Month 6 with normal cytology. 16 women excluded because of abnormal cytology results;
2 HR-HPV in HIV = positive women at Year 2. 14 women excluded because of abnormal
cytology results;
3 only 4 women were married;
4 intermediate HSV-2 results are excluded (HIV negative n = 27; HIV-positive n = 10);
5 RPR and TPHA positive;
6 oral contraceptives, injectables or implants. Reference
group includes women using condoms for family planning;
7 intermediate HSV-2 results are excluded (HIV negative n = 13; HIV positive n = 3)
Notes: Abbreviations: HR-HPV = high-risk human papillomavirus infection; LR-HPV = low-risk HPV; HIV = human immunodeficiency virus; OR = odds ratio; CI = confidence interval; FSW = female sex worker; HSV-2 =
herpes simplex virus type 2; BV = bacterial vaginosis; N.A = not applicable. Sample sizes for different questions may vary slightly from the total N based on missing responses.
Classification of HR-HPV is independent of LR-HPV status. In HIV-negative HR-HPV positive women 54% had LR-HPV coinfection. In HIV-negative HR-HPV negative women 23% had LR-HPV coinfection. In HIV-positive
HR-HPV positive women 65% had LR-HPV coinfection. In HIV-positive HR-HPV negative women 44% had LR-HPV coinfection.
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4prevalence of 46% [15], as well as studies in other
regions that reported HR-HPV prevalence rates ranging
from 30-46% in HIV-negative sex workers and 44-73%
in HIV-positive sex workers [15-17]. In general,
increased HPV prevalence among HIV-positive women
can be attributed to increased susceptibility, decreased
ability to clear infection and frequent reactivation of
latent infection associated with immunosuppression
[18].
Very few prospective studies on HPV epidemiology
have been conducted in Africa. We found a cumulative
HR-HPV incidence of 28% and persistence of 32% over
a mean interval of 17 months, in HIV-negative high-risk
women. In comparison, HR-HPV incidence among a
rural Ugandan population was estimated at 7.0 per 100
PY among HIV-negative and 17.3 per 100 PY among
HIV-positive women; 66% oft h e s ei n f e c t i o n sw e r e
cleared by HIV-negative women compared to 40% by
HIV-positive women [19]. HR-HPV incidence among
HIV-negative women in Zimbabwe was estimated at
11% and persistence at 37% after 12 months of follow-
up [20]. Compared to the other two studies, our study
population had higher risk for STIs, including HPV,
because of their sexual risk behavior.
HPV52 had the highest incidence rate, the presence of
infection by HPV52, 58, and 33 combined at Month 6
was strongly associated with increased acquisition of
other HR-HPV types in Year 2. In a previous analysis of
the same cohort, the presence of HR-HPV at Month 6
was strongly associated with HIV acquisition, and
HPV52 was the most frequent HR-HPV type detected in
HIV seroconverters [21]. Infection with multiple HR-
HPV types was more common among HIV-positive
compared to HIV-negative women. Other studies have
also found higher rates of (non-16/18) HR-HPV types in
HIV-positive compared to HIV-negative women, as well
as higher rates of infections with multiple types
[4,17,22-25].
In our study, prior C. trachomatis and N. gonorrhoeae
infection were associated with HR-HPV prevalence in
HIV-negative women, and prior C. trachomatis infection
with HR-HPV incidence. The literature is mixed, with
some studies finding associations between C. trachoma-
tis and HR-HPV [26,27], and others not [28]. The biolo-
gical interactions between C. trachomatis infection and
HPV infection are not yet fully understood [29,30].
Inflammatory changes of cervical epithelium, microabra-
sions of the epithelium and host immune response may
Table 2 Type-specific high-risk HPV prevalence and incidence among HIV-negative high-risk women with normal
cytology, Kigali, Rwanda
Prevalence* Incidence†
No at risk No cases Prevalence proportion % (95% CI) No at risk No cases Incidence proportion % (95% CI)
Any HR 349 105 31 (26-36) 296 82 28 (23-33)
Alpha 9 (HPV-16-related types)
16 349 19 5 (3-8) 282 12 4 (2-7)
31 349 11 3 (1-5) 286 10 3 (1-6)
33 349 7 2 (1-4) 289 8 3 (1-5)
35 349 12 4 (2-6) 285 4 1 (0-3)
52 349 15 4 (2-6) 287 16 6 (3-8)
58 349 14 4 (2-6) 284 10 4 (1-6)
Alpha 7 (HPV-18 related types)
18 349 11 3 (1-5) 289 13 4 (2-7)
39 349 8 2 (1-4) 290 5 2 (0-3)
45 349 17 5 (3-7) 281 7 2 (1-4)
59 349 11 3 (1-5) 286 12 4 (2-7)
68 349 13 4 (2-6) 286 7 2 (1-4)
Other types
51 349 12 4 (2-6) 287 11 4 (2-6)
56 349 8 2 (1-4) 290 8 3 (1-5)
73 349 5 1 (0-3) 291 3 1 (0-2)
82 349 1 0 (0-1) 295 3 1 (0-2)
Iso39 349 1 0 (0-1) 295 1 0 (0-1)
*Type-specific prevalence at M6 visit. Population at risk includes HIV-negative women with/without HR-HPV co-infection with other types than the type at
interest; †Type-specific incidence. Population at risk includes HIV-negative women with/without HR-HPV infection with other types than the type at interest.; 320
women had HPV results at M6 and Year 2; 15 were excluded because of abnormal cytology results; another 9 because HIV seroconversion; mean interval
incidence 16.6 months (SD 1.8)
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Page 10 of 14Table 3 Predictors of HR-HPV incidence and persistence in HIV-negative high-risk women with normal cytology, Kigali,
Rwanda
Incidence
1 Persistence
2
Incident cases Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Persistent cases Unadjusted OR
(95% CI)
n/N N = 296 N = 295 n/N N = 90
Demographical and reproductive characteristics at baseline
Age
< 30 75/243 1 1 27/81 1
≥ 30 yrs 7/53 0.34 (0.15-0.80) 0.44 (0.18-1.06) 2/9 0.57 (0.11-2.98)
Age at sexual debut
< 15 10/39 1 2/16 1
15-19 63/213 1.22 (0.56-2.65) 24/65 4.10 (0.82-20.50)
≥ 20 8/41 0.70 (0.24-2.04) 2/8 2.33 (0.24-22.27)
Parity
< 3 pregnancies 58/188 1 18/62 1
≥ 3 pregnancies 24/108 0.64 (0.37-1.11) 11/28 1.58 (0.61-4.07)
HPV infection at Month 6 (first HPV measurement)
LR-HPV
Negative 44/199 1 11/39 1
Positive 38/97 2.27 (1.33-3.88) 18/51 1.39 (0.58-3.45)
HR-HPV co-infections
3
Negative 51/206 1 16/57 1
Positive 31/90 1.59 (0.93-2.74) 13/33 1.67 (0.67-4.17)
HR HPV 33 and/or 52 and/or 58
4
Negative 66/269 1 1
Positive 16/27 4.47 (1.93-10.35) 4.10 (1.73-9.75)
Neisseria gonorrhoeae by PCR
Negative 76/266 1 25/75 1
Positive 5/23 0.69 (0.25-1.94) 4/9 1.73 (0.42-7.08)
Chlamydia trachomatis by PCR
Negative 79/280 1 28/88 1
Positive 2/12 0.51 (0.11-2.39) 1/2 2.14 (0.13-36.25)
Trichomonas vaginalis by InPouch culture
Negative 74/245 1 24/72 1
Positive 8/48 0.46 (0.20-1.04) 5/7 0.83 (0.26-2.66)
Syphilis serology
Negative 75/272 1 27/81 1
Positive 5/20 0.88 (0.31-2.50) 2/7 0.80 (0.14-4.44)
BV by Nugent score
Normal (score 0-3) 35/127 1 11/31 1
Intermediate flora (score 4-6) 5/39 0.39 (0.14-1.08) 4/11 1.04 (0.24-4.43)
BV (score 7-10) 35/108 1.26 (0.72-2.21) 12/42 0.73 (0.27-1.99)
Genital co-infection at M12
Neisseria gonorrhoeae by PCR
Negative 73/270 1 23/77 1
Positive 9/25 1.52 (0.64-3.60) 6/13 2.1 (0.60-6.75)
Chlamydia trachomatis by PCR
Negative 73/277 1 1 28/84 1
Positive 9/18 2.79 (1.06-7.38) 2.90 (1.03-8.14) 1/6 0.40 (0.04-3.66)
Trichomonas vaginalis by InPouch culture
Negative 76/273 1 26/80 1
Positive 4/19 0.69 (0.22-2.15) 3/9 1.03 (0.24-4.52)
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Page 11 of 14Table 3 Predictors of HR-HPV incidence and persistence in HIV-negative high-risk women with normal cytology, Kigali,
Rwanda (Continued)
Syphilis serology
Negative 79/275 1 27/82 1
Positive 1/17 0.16 (0.02-1.21) 2/6 1.02 (0.17-5.97)
BV by Nugent score
Normal (score 0-3) 30/123 1 17/32 1
Intermediate flora (score 4-6) 11/33 1.55 (0.67-3.58) 2/8 0.29 (0.05-1.80)
BV (score 7-10) 34/105 1.48 (0.83-2.66) 9/43 0.23 (0.08-0.69)
Current (Year 2) sexual and reproductive characteristics
Female sex worker (self-identified)
6
No 8/63 1 1 6/21 1
Yes 74/233 3.20 (1.43-7.16) 3.01 (1.32-6.83) 23/69 1.25 (0.43-3.67)
Sexually active
7
No 4/24 1 1/8 1
Yes 78/272 2.01 (0.66-6.10) 28/82 3.63 (0.41-21.96)
No. of clients in the past week
0 8/62 1 6/21 1
1-4 35/102 3.53 (1.47-8.46) 7/26 0.92 (0.25-3.37)
5-9 17/61 2.61 (1.01-6.74) 5/19 0.89 (0.22-3.66)
≥ 10 22/70 3.09 (1.23-7.79) 11/24 2.12 (0.59-7.58)
No of vaginal sex acts in past month
0 4/24 1 1/8 1
1-24 50/176 1.98 (0.647-6.14) 13/48 2.60 (0.28-24.06)
≥ 25 28/90 2.26 (0.70-7.33) 15/32 6.18 (0.60-63.4)
Condom use during vaginal sex in the past month
Always 21/66 1 4/14 1
Never/inconsistent 56/199 0.84 (0.46-1.54) 23/65 1.37 (0.38-4.90)
No sex 5/31 0.41 (0.14-1.25) 2/11 0.56 (0.08-4.01)
Hormonal contraceptive use
8
No 57/195 1 17/57 1
Yes 23/98 0.74 (0.42-1.30) 12/32 1.41 (0.56-3.55)
BV by Nugent score
Normal (score 0-3) 35/144 1 14/37 1
Intermediate flora (4-6) 6/21 1.25 (0.45-3.47) 2/6 0.82 (0.13-5.20)
BV (score 7-10) 38/124 1.38 (0.80-2.37) 13/46 0.65 (0.25-1.65)
Concurent LR HPV infection
No 36/87 1 1 18/55 1
Yes 46/209 2.50 (1.44-4.33) 2.41 (1.34-4.34) 11/35 0.94 (0.38-2.35)
HSV-2 serology
Negative Enr-Year 2 26/96 1 6/19 1
Positive at Enr 41/158 0.94 (0.53-1.68) 17/50 1.12 (01.36-3.49)
Incident at Year 2 7/14 2.69 (0.84-8.60) 3/8 1.30 (0.22-7.58)
1 Incidence is composite grouped-type specific incident variable including HIV-negative women with normal cytology who develop at least one incident
infection. Population at risk includes women with/without HR-HPV co-infection with other types than the type at interest; mean interval incidence 16.6 months
(SD 1.8);
2 Persistence is a composite grouped-type-specific persistence variable, including HIV-negative women with normal cytology who are at risk of at least
one persistent infection. The population at risk includes women with/without HR-HPV co-infection with other types than the type at interest; mean interval
ersistence 16.9 months (SD 1.7);
3 No HR-HPV infection at Month 6 compared to ≥ 1 types detected for HPV incidence model - and a single HR-HPV infection at
Month 6 compared to ≥ 2 types for HPV persistence model;
4 Reference group: no HR-HPV at Month 6. Other prevalent HR-HPV types were not associated with
acquisition of new HR HPV types;
5 Reference group: all others;
6 31/296 women in incidence model stopped sex work since last study visit - and 23/99 women
in persistence analysis;
7 24/296 women reported no sexually activity at Year 2 visit in incidence analysis; 8/99 reported no sexual activity at Year 2 visit in
persistence analysis;
8 Oral contraceptives, injectables or implants
Abbreviations: HR-HPV = high-risk human papillomavirus infection; LR-HPV = low-risk HPV; HIV = human immunodeficiency virus; OR = odds ratio; CI =
confidence interval; HSV-2 = herpes simplex virus type 2; ASCUS = atypical squamous cells of undetermined significance; Sample sizes for different questions
may vary slightly from the total N based on missing responses.
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Page 12 of 14facilitate (re) uptake of HPV and/or impede clearance
[27,30]. Most women in our study had either received
treatment or spontaneously cleared the C. trachomatis
infection by the next visit. Active epithelial regeneration
following infection might increase the susceptibility of
target cells to HPV. Conversely, insufficient Th1 cells
responses (which are required for resolving C. tracho-
matis infection and clearing HPV) may promote persis-
tent C. trachomatis and persistent HPV infection
[31-33]. As the majority of C. trachomatis infections in
our population were treated or cleared, we were not
able to establish an association between persistent C.
trachomatis infection and HPV persistence. We also did
not find an association between BV and any or HR-
HPV, as has been found in other studies [34,35]. Sexual
behavior indicators (number of clients, number of vagi-
nal sex acts, condom use, age at sexual debut, years as
F S W )w e r en o ta s s o c i a t e dw ith HR-HPV prevalence
among this highly sexually active population.
There is no consistent definition of HPV persistence
in the scientific literature, with some published studies
using a duration of 6-12 months, and others using a
duration of longer than 12 months [36]. The mean
interval between the two HPV measurements in our
study was approximately 17 months. With this long
duration, the extent of persistence may have been
overestimated because we cannot exclude re-activation
or re-infection after clearance of the initial infection.
In addition, left censoring, by using prevalent HPV
infections, may have further inflated our persistence
results because long-term infections are often over-
represented among prevalent cases. In contrast, the
incidence rate may have been underestimated because
some women may have acquired new infections but
cleared them before the second HPV test was per-
formed. Furthermore, our type-specific prevalence and
incidence rates are imprecise due to small sample
sizes.
Conclusion
In conclusion, high HPV prevalence, incidence and per-
sistence rates were found in this study among high-risk
women in Kigali. HPV52 had the highest incidence; and,
together with HPV33 and HPV58, was strongly asso-
ciated with acquisition of other HR-HPV types in HIV-
negative women. HPV52 and 58 were also the most pre-
valent in HIV-positive women and, as previously shown,
in HIV seroconverters. In addition, prior C. trachomatis
was associated with HR-HPV incidence.
Women at high-risk for sexually transmitted infections
(including HIV) experience a higher incidence and pre-
valence of HPV infections, including infections with
high-risk HPV types. Therefore these women are at
greater risk for developing cervical cancer. Cervical
cancer prevention programs should incorporate strate-
g i e st oe n s u r eah i g hc o v e r a g ea m o n gt h e s eh i g h - r i s k
women.
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